- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.10. | An effective analytical testing strategy for viral vectors should include these 7 steps | ||
| 07.10. | Best practices for developing safety profiles in rare disease trials | ||
| 04.10. | Editas trades Vertex fees for upfront cash in DRI deal | ||
| 04.10. | Sanofi's rare disease drug finds yet another home | ||
| 04.10. | Opdivo gets 'perioperative' approval; pharmas cut jobs in New Jersey, Ireland | ||
| 04.10. | An Alzheimer's drugmaker is accused of data manipulation. Should its trials be stopped? | ||
| 03.10. | Medicare tweaks rules for second round of drug price talks | ||
| 03.10. | FDA makes end of Zepbound, Mounjaro shortage official | ||
| 02.10. | Gilead agrees to license new HIV drug in low-income countries | ||
| 02.10. | Lilly plans $4.5B 'foundry' for advanced drug manufacturing | ||
| 02.10. | How Roche plans to fill a projected $8B sales gap | ||
| 02.10. | With $115M more, Triveni accelerates immune drug work | ||
| 01.10. | The top biopharma conferences in 2025 | ||
| 01.10. | IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply | ||
| 01.10. | Kailera Therapeutics emerges from stealth with $400M for obesity drugs | ||
| 01.10. | J&J drops 340B rebate plan after government pressure | ||
| 01.10. | 5 FDA decisions to watch in the fourth quarter | ||
| 30.09. | Roche turns to a startup in search for new breast cancer drugs | ||
| 30.09. | Aktis raises $175M to fuel radiopharma drug development | ||
| 30.09. | Prime to narrow gene editing research as it strikes deal with Bristol Myers | ||
| 30.09. | Key factors shaping the future of clinical services organizations in the APAC market | ||
| 30.09. | Accelerating precision oncology: The value of an end-to-end partner for therapeutic access | ||
| 27.09. | J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers | ||
| 27.09. | FDA, after delay, clears Regeneron and Sanofi drug for COPD | ||
| 27.09. | Bristol Myers schizophrenia drug, the first of its kind, approved by FDA |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
